Open AccessEvaluation of efficacy, safety, and tolerability of fixed dose combination (FDC) of halometasone 0.05% and fusidic acid 2% w/w topical cream versus FDC of betamethasone valerate 0.12% and neomycin sulphate 0.5% w/w topical cream in the treatment of infected eczematous dermatosis in Indian subjects: A randomized open-label comparative phase III multi-centric trial
Author(s) -
D. V. S. Pratap,
Mariam Philip,
Narayana T Rao,
Hemangi Jerajani,
Sainath A Kumar,
Maria Kuruvila,
Latha Subramanya Moodahadu,
Shilpi Dhawan
Publication year - 2013
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/0019-5154.108041
Subject(s) - medicine , fusidic acid , tolerability , group b , adverse effect , dermatology , fixed dose combination , group a , gastroenterology , staphylococcus aureus , biology , bacteria , genetics
To evaluate the efficacy and safety of fixed drug combination (FDC) halometasone 0.05% and fusidic acid 2% (group A) vs FDC betamethasone 0.12% and neomycin sulfate 0.5% cream (group B) in acute or chronic infected eczematous dermatosis, through a randomized open-label, comparative, multicentric study.